secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103543
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus Q2 rev $378M, adj EPS $1.57; cuts FY25 guidance; FDA NDA acceptance; $400M buyback
--------------------------------------------------------------------------------

- Q2 revenue $378.0M (-4.1% YoY); GAAP EPS $1.12; adjusted EPS $1.57.
- PYLARIFY sales $250.6M (-8.3%); DEFINITY sales $83.9M (+7.5%).
- FY25 revenue guidance cut to $1.475-$1.51B from $1.55-$1.585B; adj EPS to $5.50-$5.70 from $6.60-$6.70.
- FDA accepted NDA for new piflufolastat F 18 formulation; PDUFA date March 6, 2026; batch size +~50%.
- Board authorized $400M share repurchase program through Dec 2027, replacing prior $400M program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000095017025103543/0000950170-25-103543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000095017025103543/lnth-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer